Cytokinetics (CYTK)

• Market cap: $4.48B
• 1 day: -4.23%
• 5 days: -3.08%
• 1 month: -16.77%
• 3 months: -17.48%
• 6 months: -29.73%
• Year to date: -22.73%
• 1 year: -42.96%
• 5 years: 151.73%
• 10 years: 412.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Employees: 498

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

77% more call options, than puts

Call options by funds: $182M | Put options by funds: $103M

4% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 47

0% more funds holding in top 10

Funds holding in top 10: 15 [Q3] → 15 (+0) [Q4]

0% less funds holding

Funds holding: 344 [Q3] → 343 (-1) [Q4]

9% less repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 131

6.69% less ownership

Funds ownership: 117.95% [Q3] → 111.26% (-6.69%) [Q4]

14% less capital invested

Capital invested by funds: $7.15B [Q3] → $6.18B (-$966M) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $54 43% upside
• Avg. target: $79 110% upside
• High target: $120 217% upside

8 analyst ratings

• positive: 7 88%
• neutral: 1 13%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 14% 1-year accuracy 58 / 415 met price target	217% upside $120	Buy Reiterated	21 Apr 2025
B of A Securities Jason Zemansky 50% 1-year accuracy 5 / 10 met price target	43% upside $54	Neutral Maintained	15 Apr 2025
JMP Securities Jason Butler 50% 1-year accuracy 2 / 4 met price target	106% upside $78	Market Outperform Reiterated	10 Apr 2025
Needham Serge Belanger 37% 1-year accuracy 45 / 123 met price target	90% upside $72	Buy Reiterated	8 Apr 2025
Citizens Capital Markets Jason Butler 50% 1-year accuracy 2 / 4 met price target	106% upside $78	Market Outperform Reiterated	3 Apr 2025